Skip to main content

BRIEF RESEARCH REPORT article

Front. Oncol.
Sec. Pediatric Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1367159

Proteomic analysis of serum small extracellular vesicles identifies diagnostic biomarkers for neuroblastoma

Provisionally accepted
Juan Cheng Juan Cheng 1*Dongrui Ji Dongrui Ji 2Wanglin Zhang Wanglin Zhang 3*Jing Ma Jing Ma 4Qiuhui Pan Qiuhui Pan 1Qinghua Zhang Qinghua Zhang 2*Jinhong Wu Jinhong Wu 5Lin Yang Lin Yang 1*
  • 1 Department of Clinic Laboratory, Shanghai Children’s Medical Center, Shanghai Jiao Tong University, Shanghai, China
  • 2 Wayen Biotechnologies(Shanghai), Inc., Shanghai, China
  • 3 Department of Orthopedics, Shanghai Children's Medical Center, Shanghai, China
  • 4 Department of Pathology, Shanghai Children's Medical Center, Shanghai, China
  • 5 Department of Respiratory Medicine, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

The final, formatted version of the article will be published soon.

    Background Neuroblastoma (NB) primarily arises in children who are <10 years of age, and originates from developing sympathetic nervous system, which results in tumors in adrenal glands and/or sympathetic ganglia. The diagnosis of NB involves a combination of laboratory and imaging tests, and biopsies. Small extracellular vesicles (sEVs) have gained attention as potential biomarkers for various types of tumors. Here, we performed proteomic analysis of serum sEVs and identified potential biomarkers for NB.Methods Label-free proteomics of serum sEVs were performed in the discovery phase.A bulk RNA-seq dataset of NB tissues was used to analyze the association between genes encoding sEVs proteins and prognosis. Potential biomarkers were validated via multiple reaction monitoring (MRM) or western blot analysis in the validation phase.A public single-cell RNA-seq (scRNA-seq) dataset was integrated to analyze the tissue origin of sEVs harboring biomarkers.Results A total of 104 differentially expressed proteins were identified in NB patients with label-free proteomics, and 26 potential biomarkers were validated with MRM analysis. Seven proteins BSG, HSP90AB1, SLC44A1, CHGA, ATP6V0A1, ITGAL and SELL showed the strong ability to distinguish NB patients from healthy controls and non-NB patients as well. Integrated analysis of scRNA-seq and sEVs proteomics revealed that these sEVs-derived biomarkers originated from different cell populations in tumor tissues.representing an innovative strategy to improve NB detection and management.

    Keywords: Neuroblastoma, extracellular vesicles, Proteomics, biomarker, Pediatrics

    Received: 08 Jan 2024; Accepted: 30 Jul 2024.

    Copyright: © 2024 Cheng, Ji, Zhang, Ma, Pan, Zhang, Wu and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Juan Cheng, Department of Clinic Laboratory, Shanghai Children’s Medical Center, Shanghai Jiao Tong University, Shanghai, China
    Wanglin Zhang, Department of Orthopedics, Shanghai Children's Medical Center, Shanghai, China
    Qinghua Zhang, Wayen Biotechnologies(Shanghai), Inc., Shanghai, China
    Lin Yang, Department of Clinic Laboratory, Shanghai Children’s Medical Center, Shanghai Jiao Tong University, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.